Insulet Corporation (NASDAQ:PODD) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have earned a consensus rating of “Moderate Buy” from the twenty-seven analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and twenty-one have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $252.4783.

Several research firms recently weighed in on PODD. Jefferies Financial Group cut their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Barclays lowered their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Bank of America lowered their price target on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Wall Street Zen upgraded Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th.

Hedge Funds Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Larson Financial Group LLC increased its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. bought a new position in Insulet during the fourth quarter valued at about $26,000. Elyxium Wealth LLC bought a new position in Insulet during the fourth quarter valued at about $28,000. DV Equities LLC bought a new stake in shares of Insulet in the 4th quarter valued at approximately $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet in the 4th quarter valued at approximately $29,000.

Insulet Price Performance

NASDAQ PODD opened at $146.01 on Thursday. Insulet has a twelve month low of $141.02 and a twelve month high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a market capitalization of $10.11 billion, a PE ratio of 33.96, a P/E/G ratio of 1.22 and a beta of 1.20. The stock has a 50-day simple moving average of $187.01 and a 200 day simple moving average of $247.26.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Research analysts anticipate that Insulet will post 6.43 EPS for the current year.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: William Blair initiated coverage on Insulet with an Outperform rating, saying the valuation gap is hard to justify. William Blair Initiates on Insulet (PODD) With Outperform and Says the Valuation Gap Is Hard to Justify
• Positive Sentiment: Royal Bank of Canada reaffirmed an Outperform rating and set a $280 price target, signaling confidence in meaningful upside. Benzinga report on RBC reaffirming Insulet
• Positive Sentiment: Analysts have highlighted Omnipod 5 as a key growth driver, with prior quarterly results showing a beat and raised 2026 outlook. PODD and Omnipod 5: What’s Driving Insulet’s 2026 Growth
• Neutral Sentiment: Insulet said management will present at the William Blair Growth Stock Conference on June 3, which may keep investor attention on the company’s growth strategy. Insulet to Participate in William Blair 46th Annual Growth Stock Conference
• Negative Sentiment: Insulet announced a voluntary correction for specific Omnipod 5, DASH, and Eros pods after identifying a manufacturing issue that could cause under-delivery of insulin. Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod Pods
• Negative Sentiment: Reuters said the defect could cost Insulet up to $50 million, reinforcing concerns about recall expenses and execution risk. Insulet flags dosing defect in some Omnipod devices, sees up to $50 million cost

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.